UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Clinical Insights Into Novel Immune Checkpoint Inhibitors

Frontiers in pharmacology, 2021-05, Vol.12, p.681320-681320

2021

Volltextzugriff (PDF)

Role and Function of O-GlcNAcylation in Cancer

Cancers, 2021-10, Vol.13 (21), p.5365

2021

Volltextzugriff (PDF)

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

Cancer discovery, 2022-01, Vol.12 (1), p.16-19

2022

Volltextzugriff (PDF)

Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107862, Article 107862

2024

Volltextzugriff (PDF)

Management of HER2 alterations in non-small cell lung cancer – The past, present, and future

Lung cancer (Amsterdam, Netherlands), 2023-12, Vol.186, p.107385-107385, Article 107385

2023

Volltextzugriff (PDF)

Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma

Scientific reports, 2021-04, Vol.11 (1), p.8551-8551, Article 8551

2021

Volltextzugriff (PDF)

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359241240657-17588359241240657

2024

Volltextzugriff (PDF)

Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types

Frontiers in immunology, 2024, Vol.15, p.1330228-1330228

2024

Volltextzugriff (PDF)

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

Frontiers in immunology, 2024-03, Vol.15, p.1336246-1336246

2024

Volltextzugriff (PDF)

Publisher Correction: Overexpression of PVR and PD‑L1 and its association with prognosis in surgically resected squamous cell lung carcinoma

Scientific reports, 2021-07, Vol.11 (1), p.15552-15552, Article 15552

2021

Volltextzugriff (PDF)

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia

The Korean Journal of Internal Medicine, 2021, 36(6), , pp.1450-1458

2021

Volltextzugriff (PDF)

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

JTO clinical and research reports, 2024-02, Vol.5 (2), p.100628, Article 100628

2024

Volltextzugriff (PDF)

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies

Cancers, 2023-09, Vol.15 (18), p.4663

2023

Volltextzugriff (PDF)

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

Frontiers in oncology, 2022-03, Vol.12, p.821391-821391

2022

Volltextzugriff (PDF)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial

Trials, 2020-04, Vol.21 (1), p.320-7, Article 320

2020

Volltextzugriff (PDF)

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Journal for immunotherapy of cancer, 2019-10, Vol.7 (1), p.268-268, Article 268

2019

Volltextzugriff (PDF)

Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis

Frontiers in oncology, 2021-01, Vol.10, p.609313

2021

Volltextzugriff (PDF)

Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?

Journal of thoracic oncology, 2024-04, Vol.19 (4), p.525-527

2024

Volltextzugriff (PDF)

Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea

Cancer treatment and research communications, 2023-01, Vol.36, p.100715-100715, Article 100715

2023

Volltextzugriff (PDF)

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

Therapeutic advances in medical oncology, 2022-01, Vol.14, p.17588359221141761-17588359221141761

2022

Volltextzugriff (PDF)

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)

The Korean Journal of Internal Medicine, 2022, 37(1), , pp.190-200

2022

Volltextzugriff (PDF)

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment

Frontiers in chemistry, 2022-12, Vol.10, p.998013-998013

2022

Volltextzugriff (PDF)

Prognostic implications of PD-L1 expression in patients with angiosarcoma

Future science OA, 2021-06, Vol.7 (5), p.FSO691-FSO691

2021

Volltextzugriff (PDF)

Foritinib, a type II ROS1 inhibitor for NSCLC

The lancet respiratory medicine, 2024-09, Vol.12 (9), p.656-657

2024

Volltextzugriff (PDF)

Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC

Journal of thoracic oncology, 2024-03, Vol.19 (3), p.376-379

2024

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(66)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Oncology
(25)
Humans
(17)
Chemotherapy
(9)
Immunotherapy
(8)
Non-Small Cell Lung Cancer
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Lung Neoplasms - Drug Therapy
(7)
Mutation
(7)
Lung Neoplasms - Genetics
(6)
Respiratory System
(6)
Cancer
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Lung Cancer
(5)
Aged
(4)
Biomarkers
(4)
Carcinoma, Non-Small-Cell Lung - Pathology
(4)
Erbb Receptors - Genetics
(4)
Immunology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Clinical Insights Into Novel Immune Checkpoint Inhibitors

Role and Function of O-GlcNAcylation in Cancer

Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC

Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities

Management of HER2 alterations in non-small cell lung cancer – The past, present, and future

Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma

Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer

Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

Publisher Correction: Overexpression of PVR and PD‑L1 and its association with prognosis in surgically resected squamous cell lung carcinoma

Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia

Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report

Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies

Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis

Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage?

Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)

YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment

Prognostic implications of PD-L1 expression in patients with angiosarcoma

Foritinib, a type II ROS1 inhibitor for NSCLC

Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC

Suchergebnisse filtern